Dennis Hulme
Stock Analyst at Taylor Collison
(0.94)
# 3,748
Out of 4,455 analysts
12
Total ratings
36.4%
Success rate
-6.3%
Average return
Main Sectors:
Stocks Rated by Dennis Hulme
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: IMR Imricor Medical Systems, Inc. | Maintained: Buy | $2.78 → $3.45 | $1.87 | +84.99% | 3 | May 15, 2026 | |
| ASX: TLX Telix Pharmaceuticals Limited | Maintained: Buy | $19.61 | $15.33 | n/a | 1 | Aug 26, 2024 | |
| ASX: GSS Genetic Signatures Limited | Maintained: Buy | $2.19 → $2.21 | $0.058 | n/a | 3 | May 17, 2024 | |
| ASX: PER Percheron Therapeutics Limited | Maintained: Buy | $0.15 | $0.004 | n/a | 3 | Apr 4, 2024 | |
| ASX: SNT Syntara Limited | Maintained: Buy | n/a | $0.019 | n/a | 1 | Jun 21, 2023 | |
| ASX: IMM Immutep Limited | Maintained: Buy | n/a | $0.048 | n/a | 1 | Jun 10, 2022 |
Imricor Medical Systems, Inc.
May 15, 2026
Maintained: Buy
Price Target: $2.78 → $3.45
Current: $1.87
Upside: +84.99%
Telix Pharmaceuticals Limited
Aug 26, 2024
Maintained: Buy
Price Target: $19.61
Current: $15.33
Upside: n/a
Genetic Signatures Limited
May 17, 2024
Maintained: Buy
Price Target: $2.19 → $2.21
Current: $0.058
Upside: n/a
Percheron Therapeutics Limited
Apr 4, 2024
Maintained: Buy
Price Target: $0.15
Current: $0.004
Upside: n/a
Syntara Limited
Jun 21, 2023
Maintained: Buy
Price Target: n/a
Current: $0.019
Upside: n/a
Immutep Limited
Jun 10, 2022
Maintained: Buy
Price Target: n/a
Current: $0.048
Upside: n/a